公开(公告)号：US10711035B2

公开(公告)日：2020-07-14

申请号：US16682855

申请日：2019-11-13

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Gustav José Rodrigo ,  Tomas Bjorkman ,  Mats Ander ,  Jesper Ulf Hansson

IPC: A23J1/00 ,  C07K1/22 ,  C07K16/00 ,  C07K14/31 ,  B01J20/28 ,  B01J20/24 ,  B01J20/32 ,  B01D15/38 ,  C07K17/10 ,  B01J20/286 ,  C07K16/06

Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.

公开(公告)号：US10654887B2

公开(公告)日：2020-05-19

申请号：US15282367

申请日：2016-09-30

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Gustav Jose Rodrigo ,  Tomas Bjorkman ,  Mats Ander ,  Jesper Ulf Hansson

IPC: C07K1/22 ,  B01J20/26 ,  C07K16/00 ,  C07K14/31 ,  B01J20/32 ,  B01J20/285 ,  B01J20/286 ,  C07K16/12 ,  C07K17/10

Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.

公开(公告)号：US20200079878A1

公开(公告)日：2020-03-12

申请号：US16594731

申请日：2019-10-07

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Gustav Rodrigo ,  Tomas Bjorkman ,  Mats Ander

IPC: C07K16/46 ,  C07K16/00 ,  C07K14/31 ,  C07K1/22 ,  C07K16/06 ,  B01D15/38 ,  B01J20/32 ,  B01J20/289

Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO 51 or SEQ ID NO 52 wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO:4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.

公开(公告)号：US10513537B2

公开(公告)日：2019-12-24

申请号：US16096952

申请日：2017-05-10

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Gustav José Rodrigo ,  Tomas Bjorkman ,  Mats Ander ,  Jesper Ulf Hansson

IPC: A23J1/00 ,  C07K1/22 ,  C07K16/00 ,  C07K14/31 ,  B01J20/28 ,  B01J20/24 ,  B01D15/38 ,  C07K16/06 ,  C07K17/10

Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.

公开(公告)号：US20190381480A1

公开(公告)日：2019-12-19

申请号：US16486653

申请日：2018-02-15

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Ronnie Palmgren ,  Jean-Luc Maloisel ,  Gustav Rodrigo ,  Tomas Bjorkman

IPC: B01J20/286 ,  B01D15/38 ,  B01J20/28 ,  B01J20/32 ,  B01D15/18 ,  C07K1/22

Abstract: A separation matrix comprising porous particles to which antibody-binding protein ligands have been covalently immobilized, wherein the density of said ligands is above 5 mg/ml, the volume-weighted median diameter of said porous particles is at least 10 and below 30 μm and the said porous particles have a gel phase distribution coefficient, expressed as KD for dextran of molecular weight 110 kDa, of 0.5-0.9.

公开(公告)号：US20190144496A1

公开(公告)日：2019-05-16

申请号：US16096869

申请日：2017-05-10

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Gustav José Rodrigo ,  Tomas Bjorkman ,  Mats Ander

IPC: C07K1/22 ,  C07K17/10 ,  B01J20/285 ,  B01J20/286 ,  C07K16/12 ,  B01J20/26 ,  C07K14/31 ,  C07K16/00

Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO 51 or SEQ ID NO 52, wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO: 4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.

公开(公告)号：US10189891B2

公开(公告)日：2019-01-29

申请号：US14385336

申请日：2013-03-26

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Mats Ander ,  Goran Bauren ,  Tomas Bjorkman ,  Per-Mikael Aberg ,  Gustav Rodrigo

IPC: C07K1/22 ,  C07K14/31 ,  C07K16/00 ,  B01J20/286 ,  B01D15/38 ,  B01J20/291 ,  G01N33/68 ,  B01J20/32

Abstract: The invention discloses an immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal Protein A (E, D, A, B, C) or protein Z or a functional variant thereof, wherein in at least one of the one or more mutated monomers, the asparagine or histidine at the position corresponding to H18 of the B domain of Protein A or of Protein Z has been deleted or substituted with a first amino acid residue which is not proline or asparagine and wherein, if the amino acid residue at position 57 is proline and the amino acid residue at position 28 is asparagine, then the amino acid residue at the position corresponding to H18 of the B domain of protein A or of protein Z is not serine, threonine or lysine.